GlassScriptPhysician profile
Pinakin Gunvant Davey
NPI 1659685733
$242,955.22
in general payments reported to CMS, 2019-2025
24 companies · $43K in 2025
The $43K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85K · 2020: $24K · 2021: $13K · 2022: $23K · 2023: $47K · 2024: $8,381 · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Travel and Lodging: $22K · Consulting Fee: $4,750 · Food and Beverage: $4,168 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,579.00 |
| Travel and Lodging | $21,829.01 |
| Consulting Fee | $4,750.00 |
| Food and Beverage | $4,167.50 |
| Education | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $143,656.45 | 2019-2025 | |
| Haag-Streit USA, INC. | $57,782.91 | 2019-2022 | |
| Optovue, INC. | $28,936.58 | 2019-2021 | |
| Thea Pharma INC. | $3,860.73 | 2023-2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,031.84 | 2019-2020 | |
| Allergan, INC. | $1,908.24 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $1,292.73 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $1,078.65 | 2022-2025 | Xiidra, Miebo, Scoutpro Osmolarity System |
| Aerie Pharmaceuticals, INC. | $674.58 | 2019-2020 | |
| Abbvie INC. | $359.73 | 2023-2025 | Vuity, Lumigan, Botox |
| Glaukos Corporation | $214.28 | 2022-2025 | Idosetr |
| Alcon Vision LLC | $168.40 | 2023-2024 | Rocklatan, Air Optix |
| Coopervision INC. | $164.04 | 2024-2025 | Clariti Contact Lens |
| Sight Sciences, INC. | $128.49 | 2023-2024 | Omni Surgical System |
| Harrow Eye, LLC | $126.00 | 2025 | Vevye |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $113.72 | 2019 | |
| Horizon Therapeutics Plc | $113.67 | 2022-2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $75.50 | 2023 | Flarex |
| Johnson & Johnson Vision Care, INC. | $75.00 | 2024 | Acuvue |
| Shire North American Group INC | $66.80 | 2019 | |
| Lombart Brothers, INC. | $44.62 | 2019 | |
| Mallinckrodt Enterprises LLC | $43.19 | 2019 | |
| Amicus Therapeutics, INC. | $19.85 | 2019 | |
| Embecta Corp. | $19.22 | 2024 | Bd Nano 2nd Gen Pen Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pinakin Davey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.